Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin in Pediatric Candida or Aspergillus Infections
NCT00082524Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2004
- Primary completion
- Jul 2007
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive aspergillosis (IA), invasive candidiasis and esophageal candidiasis, sponsored by Merck & Co. Primary endpoint: Proportion of patients with one or more drug-related clinical or laboratory adverse experience(s). Started Apr 2004; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)invasive candidiasisesophageal candidiasis
Beyond the preview
Go deeper on NCT00082524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082524.